Article Information
PubMed
Published By
History
- Received September 4, 2024
- Accepted October 4, 2024
- Published online October 30, 2024.
Article Versions
- previous version (October 21, 2024 - 05:55).
- You are viewing the most recent version of this article.
Copyright & Usage
Copyright: © 2024 The Authors This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License.
Author Information
Funding
China Postdoctoral Science Foundation
2023T160788Beijing Science and Technology Plan
Z181100001718215
This study was supported by the China Postdoctoral Science Foundation (Grant No. 2023T160788) and the Beijing Science and Technology Plan (Grant No. Z181100001718215).
In this issue
Jump to section
- Article
- Human epidermal growth factor receptor 2 (HER2)-positive breast cancer: target drugs from meager-to-abundant
- Triple negative breast cancer (TNBC): the torchlight brought by immunotherapy
- Hormone receptor (HR)-positive breast cancer: comprehensive era of cyclin D kinase 4/6 (CDK4/6) inhibitors
- HER2 low-expression breast cancer: new field, new journey
- Conclusions
- Conflict of interest statement
- Author contributions
- References
- Figures & Data
- Info & Metrics
- References